Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) Subsidiary Receives Clinical Trial Acceptance Notice for VUM02 Injection

Stock News

Aug 04

Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Vcanbio Pharmaceutical Co., Ltd., received a Clinical Trial Application Acceptance Notice for VUM02 Injection from the Center for Drug Evaluation (CDE) of the National Medical Products Administration on August 1, 2025. The acceptance number is CXSL2500651.

VUM02 Injection (Human Umbilical Cord-Derived Mesenchymal Stromal Cell Injection) is a cryopreserved cell preparation independently developed by the company. It is a new drug composed of human umbilical cord-derived mesenchymal stromal cells (UC-MSC) prepared through screening of healthy newborn umbilical cord tissue, followed by in vitro isolation, expansion, harvesting, and cryopreservation. The clinical indication is intended for the treatment of pulmonary fibrosis after pneumonia.

As of the announcement date, no similar cell drugs for treating post-pneumonia pulmonary fibrosis have been marketed globally, with the most advanced competing drugs still in early-stage development. This indication application is supported by previously obtained clinical research data on COVID-19 and Phase I clinical trial data for idiopathic pulmonary fibrosis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1103279790"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103279790\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103279790?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-04 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103279790","market":"hk","top_or_hot":-1,"title":"Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) Subsidiary Receives Clinical Trial Acceptance Notice for VUM02 Injection","media":"Stock News","content":"<p>Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Vcanbio Pharmaceutical Co., Ltd., received a Clinical Trial Application Acceptance Notice for VUM02 Injection from the Center for Drug Evaluation (CDE) of the National Medical Products Administration on August 1, 2025. The acceptance number is CXSL2500651.</p>\n<p>VUM02 Injection (Human Umbilical Cord-Derived Mesenchymal Stromal Cell Injection) is a cryopreserved cell preparation independently developed by the company. It is a new drug composed of human umbilical cord-derived mesenchymal stromal cells (UC-MSC) prepared through screening of healthy newborn umbilical cord tissue, followed by in vitro isolation, expansion, harvesting, and cryopreservation. The clinical indication is intended for the treatment of pulmonary fibrosis after pneumonia.</p>\n<p>As of the announcement date, no similar cell drugs for treating post-pneumonia pulmonary fibrosis have been marketed globally, with the most advanced competing drugs still in early-stage development. This indication application is supported by previously obtained clinical research data on COVID-19 and Phase I clinical trial data for idiopathic pulmonary fibrosis.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) Subsidiary Receives Clinical Trial Acceptance Notice for VUM02 Injection</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) Subsidiary Receives Clinical Trial Acceptance Notice for VUM02 Injection\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-08-04 15:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Vcanbio Pharmaceutical Co., Ltd., received a Clinical Trial Application Acceptance Notice for VUM02 Injection from the Center for Drug Evaluation (CDE) of the National Medical Products Administration on August 1, 2025. The acceptance number is CXSL2500651.</p>\n<p>VUM02 Injection (Human Umbilical Cord-Derived Mesenchymal Stromal Cell Injection) is a cryopreserved cell preparation independently developed by the company. It is a new drug composed of human umbilical cord-derived mesenchymal stromal cells (UC-MSC) prepared through screening of healthy newborn umbilical cord tissue, followed by in vitro isolation, expansion, harvesting, and cryopreservation. The clinical indication is intended for the treatment of pulmonary fibrosis after pneumonia.</p>\n<p>As of the announcement date, no similar cell drugs for treating post-pneumonia pulmonary fibrosis have been marketed globally, with the most advanced competing drugs still in early-stage development. This indication application is supported by previously obtained clinical research data on COVID-19 and Phase I clinical trial data for idiopathic pulmonary fibrosis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0046","symbol_name":"生物疫苗","start_time":0,"source_url":"","article_id":"1103279790","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103279790","pubTimestamp":1754293588,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Vcanbio Pharmaceutical Co., Ltd., received a Clinical Trial Application Acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600645":"中源协和","BK0046":"生物疫苗","BK1583":"高瓴概念","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","BK0216":"研究试验","BK0239":"医药制造","BK0188":"融资融券","03347":"泰格医药","BK0042":"基因检测"},"translate_title":"Vcanbio细胞基因工程有限公司。(600645.SH)子公司收到VUM02注射液临床试验受理通知书","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600645":1,"03347":1},"content_text":"Vcanbio Cell&Gene Engineering Corp.,Ltd. (600645.SH) announced that its wholly-owned subsidiary, Wuhan Optics Valley Vcanbio Pharmaceutical Co., Ltd., received a Clinical Trial Application Acceptance Notice for VUM02 Injection from the Center for Drug Evaluation (CDE) of the National Medical Products Administration on August 1, 2025. The acceptance number is CXSL2500651.\nVUM02 Injection (Human Umbilical Cord-Derived Mesenchymal Stromal Cell Injection) is a cryopreserved cell preparation independently developed by the company. It is a new drug composed of human umbilical cord-derived mesenchymal stromal cells (UC-MSC) prepared through screening of healthy newborn umbilical cord tissue, followed by in vitro isolation, expansion, harvesting, and cryopreservation. The clinical indication is intended for the treatment of pulmonary fibrosis after pneumonia.\nAs of the announcement date, no similar cell drugs for treating post-pneumonia pulmonary fibrosis have been marketed globally, with the most advanced competing drugs still in early-stage development. This indication application is supported by previously obtained clinical research data on COVID-19 and Phase I clinical trial data for idiopathic pulmonary fibrosis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}